B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $69 and keeps a Buy rating on the shares following ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart (VXRT) to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 ...

Mayank Mamtani; Analyst; B. Riley Securities, Inc. Greetings and welcome to the Cognition Therapeutics' fourth-quarter and full-year 2024 earnings call. (Operator Instructions) As a reminder ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the call ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a “long-awaited” manufacturing agreement with ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $11 and keeps a Buy rating on the shares. The recent overwhelmingly positive Phase IIa ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...

Mayank Mamtani; Analyst; B. Riley Securities, Inc. Jack Allen; Analyst; Robert W. Baird & Co., Inc. Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter ...